Renaissance Capital logo

Landos Biopharma Priced, Nasdaq: LABP

Phase 2 biotech developing oral small molecule therapies for autoimmune diseases.

Industry: Health Care

Latest Trade: $15.38 0.00 (0.0%)

First Day Return: -25.0%

Return from IPO: -3.9%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases that are the first to target new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. We leverage our proprietary AI-based precision medicine platform, our LANCE platform, to identify novel therapeutic targets based on predictions of immunometabolic function and create therapeutic candidates to engage those targets in areas of unmet medical need. Through our LANCE platform, we have identified seven novel immunometabolic targets and product candidates to date across 14 indications. We have completed the induction phase of a Phase 2 clinical trial of our lead product candidate, BT-11, for mild to moderate UC in the United States, Russia and Europe to evaluate the efficacy and safety of BT-11 in UC patients. Data from the induction stage of this Phase 2 trial demonstrated that BT-11 was gut-restricted and well tolerated, with no treatment-related significant adverse events and a similar adverse event profile across placebo and BT-11 groups. Based on these data, we expect to commence an integrated Phase 3 trial of BT-11 in UC patients in the United States, Russia, Asia, and Europe in the first half of 2021.
more less
IPO News for Landos Biopharma
more
IPO Data
IPO File Date 01/13/2021
Offer Price $16.00
Price Range $15.00 - $17.00
Offer Shares (mm) 6.3
Deal Size ($mm) $100
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/03/2021
Offer Price $16.00
Price Range $15.00 - $17.00
Offer Shares (mm) 6.3
Deal Size ($mm) $100
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Blacksburg, VA
Founded 2017
Employees 33
Website www.landosbiopharma.com